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thus promoting both pathogenesis and 
progression of diab etes (4). IL-1β and IL-18 
are produced via cleavage of pro-IL-1β 
and pro-IL-18 by caspase-1, which in turn 
is activated by a multiprotein complex 
called the nucleotide-binding oligomeri-
zation domain (NOD)-like receptor pyrin 
domain containing 3 (NLRP3) inflamma-
some. Inflammasomes are newly identi-
fied  multi protein platforms res ponsible 
for the activation of innate infla mmatory 
pro cesses and instigation of inflammatory 
responses during a variety of chronic 
degen erative diseases (5). Among the 
inflammasomes, the most studied in the 
area of metabolic diseases is the NLRP3 
inflammasome, which comprises (a) 
NLRP3, (b) an apoptosis-associated speck-
like protein containing a caspase acti-
vation recruitment domain (ASC) and (c) 
caspase-1. The NLRP3 inflammasome 
been proposed for the treatment of these 
conditions (2,3). However, the identity 
of the specific inflammation-related sig-
naling pathways that are responsible for 
these metabolic abnormalities are still 
unknown. Cytokines of the interleukin 
(IL)-1 family, particularly IL-1β, but 
also IL-18, are among the most critical 
proinflammatory cytokines that reduce 
insulin formation by pancreatic β-cells, 
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 low-grade inflammation has a crucial role 
in the patho genesis of obesity, metabolic 
syndrome and type 2 diabetes mellitus 
(T2DM) (1). Enhanced serum concentra-
tions of proinflammatory cytokines play a 
key role in the development of metabolic 
derangements, and new antiinflammatory 
therapeutic approaches have recently 
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an enzyme-linked immunosorbent 
assay kit (ELISA) (R&D Systems). The 
albumin-to-creatinine ratio (ACR) was 
used to evaluate the urinary excre-
tion of albumin. Urine samples were 
collected at 18 h in metabolic cages, 
urine creatinine concentrations were 
determined by using a creatinine kit 
(ArborAssays) and albumin concen-
trations were determined by using a 
mouse albumin ELISA quantification 
kit (Bethyl Labs).
Western Blot analysis
Liver, kidney and gastrocnemius ex-
tracts were prepared as previously de-
scribed (12). About 60 μg total proteins 
were separated by 8% sodium dodecyl 
sulfate–polyacrylamide gel electro-
phoresis and transferred to a polyvi-
nyldenedifluoride membrane, which 
was then incubated with primary and 
secondary antibodies. To ascertain that 
blots were loaded with equal amounts 
of proteins, they were also incubated 
with antibody against β-actin or tubulin 
protein. The relative expression of the 
protein bands was quantified by densi-
tometric scanning using Gel Pro®Ana-
lyzer 4.5 (Media Cybernetics) and stan-
dardized for densitometric analysis to 
β-actin levels.
Real-Time Reverse Transcription–
Polymerase Chain Reaction
Total RNA was extracted from liver 
and kidney samples using the All-
Prep® DNA/RNA/Protein Kit (Qia-
gen) according to the manufacturer’s 
instructions. The total RNA concentra-
tion (μg/mL) was determined by the 
fluorometer Qubit and the Quant-iT™ 
RNA Assay Kit (Invitrogen). A total 
of 500 ng total RNA was reverse- 
transcribed by using the QuantiTect 
Reverse Transcription Kit (Qiagen), 
and the synthesized cDNA was used 
for real-time polymerase chain reac-
tion (PCR). The cDNA was amplified 
by  real-time PCR using SsoFast™ 
EvaGreen (Bio-Rad) and primers 
(Qiagen) specific for cytokines IL-1β 
(Mm_Il1b_2_SG, cat. no. QT01048355) 
housed in the same animal unit under 
conventional housing conditions at 
25 ± 2°C. Both the WT and KO mice were 
ran domly allocated into the follow ing 
 dietary regimens: normal diet (ND WT, 
n = 10, and ND KO, n = 4) and a high-
fat, high-fructose diet (HD WT, n = 20, 
and HD KO, n = 6) for 12 wks. They were 
provided with diet and water ad libitum. 
HD WT mice were treated with vehicle 
(n = 10) or BAY 11-7082 (HD WT+BAY, 
3 mg/kg IP 5 d/wk, n = 10) for the last 
7 wks of dietary mani pulation. The 
BAY 11-7082 dose used in this study 
was previously found to improve 
functional and biochemical deficits 
associated with experimental diabetic 
neuropathy (15). NLRP3 silencing was 
checked in all KO mice before starting 
dietary mani pulation (Supplementary 
Figure S1). The HD diet contained 45% 
kcal fat ( soybean oil and lard), 20% protein 
(casein) and 35% carbohydrate (fructose) 
(D03012907 diet, Research Diets). The 
in vivo procedures here described were 
approved by the local ethical committee 
(DGSAF 0021573-P-12/11/2013) and are 
in keeping with the European Directive 
2010/63/EU as well as the 2011 Guide for 
the Care and Use of Laboratory Animals.
Oral Glucose Tolerance Test
The oral glucose tolerance test (OGTT) 
was performed by administration of glu-
cose (2 g/kg) by oral gavage after a fasting 
period of 6 h. The concentrations of fasting 
serum glucose were measured with a con-
ventional glucometer ( GlucoMen LX kit, 
Menarini Diagnostics).
Biochemical analysis
After 12 wks of dietary manipula-
tion, the mice were anesthetized by 
using isoflurane and killed by car-
diac puncture and exsanguination. 
The plasma lipid profile was deter-
mined by measuring the content of 
triglycerides (TGs), total cholesterol, 
high-density lipoprotein (HDL) and 
low-density lipoprotein (LDL) by 
standard enzymatic procedures using 
reagent kits (Hospitex Diagnostics). 
Plasma insulin was measured by using 
plays a substantial role in sensing obesity- 
associated  inducers of caspase-1 activation 
and, therefore,  regulates the magnitude of 
the inflammatory response and hence its 
downstream effects on insulin signaling 
in different organs, including liver and 
kidney (6). The fatty acid palmitate, cho-
lesterol crystals, low- density lipoprotein 
and ceramide ( generated from fatty acids), 
which are all increased in abundance 
during nutritional excess, can each activate 
NLRP3, resulting in increased IL-1β pro-
duction (7–9). We and others have recently 
demonstrated that either a high-fat diet 
or a high-sugar diet trigger both NLRP3 
inflammasome formation and activation 
in target organs of metabolic inflamma-
tion (10–12). In addition, mice genetically 
deficient of NLRP3 are protected against 
high-fat diet–induced insulin resistance 
(9,13). Although these data suggest that the 
NLRP3 inflammasome is a central player 
in the induction of insulin resistance, its 
potential role as a pharmacological target 
for therapeutic intervention in T2DM is ill 
defined, and no selective NLRP3 inhibitors 
have been tested in preclinical models 
of metabolic disease. No studies have 
compared the effects of pharmacological 
inhibition or gene silencing of the NLRP3 
inflammasome in mice chronically fed a 
diet enriched in both sugars and saturated 
fats (high-fat, high-fructose diet [HD]), 
which are the two major components of the 
unhealthy diet that promotes obesity and 
insulin resistance. Hence, the present study 
was designed (a) to investigate the effects 
of NLRP3 inflammasome gene ablation on 
the metabolic alterations caused by chronic 
exposure to refined fat and fructose, the 
main ingredients of most processed foods, 
and (b) to determine the potential thera-
peutic value of the pharmacological mod-
ulation of NLRP3 inflammasome by the 
selective inhibitor BAY 11-7082.
MaTERiaLS aND METhODS
animals and Experimental Procedures
This study was carried out in 4- wk-old 
male NLRP3–/– knockout (KO) mice on 
C57BL/6 background (14) and NLRP3+/+ 
littermate control wild-type (WT) mice, 
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 anti-Smad2/3,  rabbit anti–phospho- 
Smad2 (Ser465/467)/Smad3 (Ser423/425) and 
rabbit  anti–β-actin were from Cell Signal-
ing Technology. Rabbit  anti– glucose trans-
porter (GLUT)-4, rabbit anti– transforming 
growth factor (TGF)-β and rabbit 
 anti- NALP3 were from Abcam. Rabbit 
anti–caspase-1 p-10 was from Santa Cruz.
Statistical analysis
All values were expressed as mean ± 
stan dard error of the mean (SEM) 
for “n” observations. The results were 
 analyzed by one-way analysis of vari-
ance followed by a Bonferroni post hoc 
test for multiple comp arisons. P <0.05 
was considered significant.
All supplementary materials are available 
online at www.molmed.org.
RESULTS
Chronic BaY 11-7082 administration 
and NLRP3 inflammasome 
Knockdown Normalized Diet–induced 
impairment of Metabolic Parameters
Wild-type mice fed with the experimen-
tal high-fat, high-sugar diet for 12 wks  
(HD WT) had greater body weights than 
control diet–fed littermates (ND WT) 
because of an increased caloric intake 
(Table 1). The body weight gain was 
slightly, but not significantly, reduced 
by BAY 11-7082. When compared with 
NLRP3–/– mice fed a normal diet (ND 
KO), NLRP3–/– mice exposed to the HD 
(HD KO) showed an increased body 
weight gain. The levels of fasting blood 
glucose and fasting serum insulin in 
Liver TG Levels
A sensitive assay kit was used to mea-
sure hepatic TGs following the provided 
protocol (Triglyceride Quantification Kit; 
Abnova Corporation).
histochemistry analysis of Collagen 
Deposition in Kidney and Liver 
Samples
Sirius red stain was performed in 4% 
formaldehyde-buffered solution fixed 
sections from kidney and liver to eval-
uate the degree of fibrosis. In the liver, 
portal tracts >100 μm in size were not 
considered, since they contain a large 
amount of collagen and therefore pre-
vent evaluation of collagen-associated 
fibrosis.
Determination of Tumor Necrosis 
Factor (TNF)-`, iL-1a, iL-6 and iL-18 
in Plasma and Tissues
Commercially available ELISA kits 
(R&D Systems) were used to measure 
concentrations of TNF-α, IL-1β, IL-6 and 
IL-18 in either plasma and tissue homog-
enates, according to the manufacturer’s 
instructions.
Materials
All compounds were from the 
Sigma- Aldrich. Mouse anti–IRS-1, 
rabbit anti–phospho-IRS1 (Ser307), 
 rabbit  anti-Akt, rabbit anti– phospho-
Akt (Ser473),  rabbit anti–glycogen 
synthase kinase (GSK)-3β, rabbit 
anti– phospho-GSK-3β (Ser9), rabbit 
 anti-AS160, rabbit anti–phospho-AS160 
(Thr642), rabbit anti–NF-κB p65, rabbit 
and IL-18 (Mm_Il18_1_SG, cat. no. 
QT00171129). The PCR protocol con-
ditions were as follows: HotStarTaq 
DNA polymerase activation step at 
95°C for 30 s, followed by 40 cycles 
at 95°C for 5 s and 55°C for 10 s. All 
samples were run in duplicate. At 
least two nontemplate controls were 
included in all PCR runs. The tran-
script of the reference gene ribosomal 
RNA 18S (Mm_Rn18s_3_SG, cat. no. 
QT02448075) was used to normalize 
mRNA data, and the quan ti fication 
data analyses were performed by 
using the Bio-Rad CFX Manager 
 Software, version 1.6 ( Bio-Rad) 
 according to the manu facturer ’s 
 instructions. These analyses were 
 performed following the MIQE guide-
lines (Minimum Information for Publi-
cation of Quantitative  Real-Time PCR 
Experiments) (16).
histological Examination of the 
Kidney and Oil Red Staining of 
the Liver
Dewaxed 5-μm sections of kidney 
were stained with hematoxylin and 
eosin and examined as previously 
described (17). Neutral lipids were 
assessed on sections of frozen liver em-
bedded in OCT (10 μm in thickness) by 
oil red O staining. The degree of fatty 
change was scored as following: mild 
when lipid droplets were observed in no 
more of 30% of the hepatocytes; mod-
erate when it compromised between 31 
and 60% of the parenchymal cells and 
severe when steatosis was observed in 
>60% of them.
Table 1. Metabolic parameters at 12 wks of dietary manipulation.
 ND WT HD WT HD+BAY WT ND KO HD KO
n 10 10 10 4 6
Body weight gain (g) 8.0 ± 0.4 14.9 ± 0.7* 12.1 ± 0.9* 7.8 ± 1.2 15.9 ± 0.8#
Food intake (g/day) 2.48 ± 0.48 2.34 ± 0.06 2.19 ± 0.10 2.72 ± 0.12 2.41 ± 0.21
Caloric intake (kcal/day) 9.23 ± 0.24 11.32 ± 0.24* 10.39 ± 0.45 9.52 ± 0.13 11.48 ± 0.19#
Serum triglyceride (mmol/L) 0.39 ± 0.04 0.60 ± 0.06* 0.40 ± 0.03§ 0.30 ± 0.04 0.37 ± 0.04
Serum total cholesterol (mmol/L) 2.08 ± 0.09 2.52 ± 0.07* 2.20 ± 0.08§ 2.02 ± 0.06 2.20 ± 0.04
Serum LDL (mmol/L) 0.76 ± 0.08 1.21 ± 0.09* 0.87 ± 0.14 0.084 ± 0.04 0.96 ± 0.05
Serum HDL (mmol/L) 1.05 ± 0.05 1.03 ± 0.07 1.01 ± 0.07 1.03 ± 0.06 1.04 ± 0.07
Data are means ± SEM. *P < 0.05 versus ND WT; §P < 0.05 versus HD WT; #P < 0.05 versus ND KO.
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glucose in either the HD+BAY WT and 
HD KO groups of mice were similar to 
those in the related control groups (ND 
WT and ND KO, respectively).
Effects of BaY 11-7082 administration 
and NLRP3 inflammasome Deficiency 
on insulin Signaling Pathway in the 
Liver and Skeletal Muscle
The levels of total expression of 
IRS-1, Akt and GSK-3β, a downstream 
target of Akt, were similar in all groups 
of mice (Figure 2) when measured in 
both liver and skeletal muscle, sug-
gesting that BAY 11-7082 treatment 
and NLRP3–/– downregulation did not 
alter the expression of the key compo-
nents of the insulin-signaling pathway. 
In contrast, significant changes in the 
degree of protein phosphorylation 
were recorded in the liver and skeletal 
muscle of WT mice exposed to HD. 
These alterations in protein phosphor-
ylation and, hence, activation status 
of the respective proteins indicate that 
HD led to an impairment in insulin 
signaling. In contrast, treatment of 
WT mice exposed to HD with BAY 
11-7082 abolished all of the alterations 
in insulin signaling caused by HD in 
vehicle-treated animals. Moreover, the 
degree of phosphorylation of IRS-1, Akt 
and GSK-3β was similar between the 
ND KO and HD KO groups of mice. 
In the gastrocnemius of WT mice, the 
impairment of insulin sensitivity due to 
dietary manipulation correlated with a 
slight reduction in GLUT-4 expression, 
which was increased after BAY 11-7082 
administration in WT mice and not 
affected by diet in KO mice (Figure 3). 
The Thr642 phosphorylation of the Akt 
substrate 160 (AS160), which is needed 
for GLUT-4 translocation to the cell 
membrane, was reduced by HD in the 
gastrocnemius of WT mice, and it was 
restored to basal levels by BAY 11-
7082, thus indicating an improvement 
in GLUT-4 translocation to the plasma 
membrane when the drug was admin-
istered to WT mice. In contrast, AS160 
phosphorylation was not affected by di-
etary manipulation in NLRP3 KO mice.
when compared with that in the HD WT 
group, although insulin levels remained 
significantly higher than that in the ND 
WT group. The OGTT revealed that gly-
cemia in the HD WT group after glucose 
challenge was higher than that in the ND 
WT group (Figure 1C). In contrast, the 
dynamic changes in the levels of blood 
both the ND KO and HD KO group were 
similar to those recorded in the ND WT 
group and were significantly lower than 
that in the HD WT group (P < 0.01; Fig-
ures 1A, B). The concentrations of fasting 
serum glucose and insulin in WT mice 
treated with BAY 11-7082 (HD+BAY WT) 
were significantly (P < 0.05) reduced 
Figure 1. Effects of chronic exposure to a normal diet (ND) or a high-fat high-sugar diet 
(HD) on serum insulin (A), blood glucose (B) and oral glucose tolerance (C), evaluated in 
NLRP3–/– KO and WT mice treated or not with BAY 11-7082 (BAY, 3 mg/kg IP). Results are 
expressed as mean ± SEM of four to five animals per group.
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whereas the same experimental diet 
did not evoke any significant change 
in the serum lipid profile of NLRP3–/– 
mice. As shown by oil red O staining 
(Figure 4A), the HD diet resulted in 
a significant lipid deposition in the 
liver. Microscopically, the intensity of 
the  steatosis was severe in almost all 
hepatocytes containing cytoplasmic 
micro- or macrovacuolar lipid droplets. 
Chronic administration of BAY 11-7082 
attenuated neutral fat accumulation, 
and no difference in lipid accumulation 
was recorded between ND KO and HD 
KO groups of mice. These effects were 
confirmed by measurement of TG con-
tent (Figure 4B). Liver oil red O staining 
as well as assessment of hepatic TG lev-
els showed no effects of the HD on lipid 
accumulation in the liver of KO mice. 
As shown in Figure 4C, the diet-induced 
lipid accumulation in the liver of WT 
mice was associated with significant 
local increase in TNF-α levels, which 
was counteracted by either pharmaco-
logical inhibition or genetic knockdown 
of the NLRP3 inflammasome.
Chronic BaY 11-7082 administration 
or ablation of NLRP3 inflammasome 
Limited Diet-induced Renal Damage
Histological analysis of kidneys from 
the HD WT group revealed a marked 
degree of vacuolar degeneration at level 
of the S1-S2 segments of the proximal 
convoluted tubules. Others tubular 
 structures of the nephrons were histolo-
gically preserved. Neither glomerular 
changes nor interstitial inflammation 
were detected (Figure 5). Kidneys of the 
BAY 11-7082–treated mice, as well as 
those from the NLRP3–/– mice, appeared 
protected against the deleterious effects 
of the dietary manipulation. Although 
vacuolar degeneration was detectable, 
it was limited to <20% of the proximal 
con voluted tubules examined. The re-
maining parenchyma did not show any 
signi ficant alterations. When compared 
with ND WT mice, WT mice subjected 
to HD demonstrated a significant in-
crease in the  albumin-to-creatinine 
ratio (ACR), which is an indicator of 
serum TG levels as well as a robust 
increase in total cholesterol and LDL 
concentrations in comparison with ND 
WT mice (Table 1). The diet-induced 
changes in serum lipid profile were 
suppressed by the pharmacological 
inhibition of NLRP3 inflammasome, 
Chronic BaY 11-7082 administration 
or ablation of NLRP3 inflammasome 
Reduced Diet-induced Dyslipidemia 
and hepatic Lipid accumulation
Concurrent with the development 
of insulin resistance, HD-fed WT ani-
mals displayed a two-fold increase in 
Figure 2. Effects of diet manipulation and NLRP3 inflammasome inhibition or silencing on 
insulin signal transduction in liver and skeletal muscle. Western blot analysis of total IRS-1 
and Ser307 phosphorylation (A), total Akt and Ser473 phosphorylation (B) and total GSK-3β 
and Ser9 phosphorylation (C) were performed in the liver and gastrocnemius of NLRP3–/– 
KO and WT mice treated or not with BAY 11-7082 (BAY, 3 mg/kg IP). The relative expres-
sion of the protein bands was expressed as relative optical density (O.D.) and standard-
ized to the corresponding β-actin contents. The data are means ± SEM of pooled data 
from three separate experiments (n = 4–6 mice per group). ★P < 0.05 versus ND WT.
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Chronic BaY 11-7082 administration 
or ablation of NLRP3 inflammasome 
Reduced Diet-induced 
Overexpression of Profibrotic Markers 
in Liver and Kidney
As shown in Figure 6, Western blot 
analysis of the expression levels of 
TGF-β in the liver and kidney of WT 
mice demonstrated a significant increase 
in this profibrotic marker after dietary 
manipulation, which led to downstream 
phosphorylation of Smad2, suggestive 
of activation. However, these effects did 
not lead to a marked fibrotic process in 
the liver, at least when determined at 
12 wks, since no difference among the 
groups was shown in the amount of col-
lagen detected in the portal spaces and 
around the terminal hepatic venules; 
and the acinar structure of the liver was 
preserved. In contrast, kidneys of WT 
mice exposed to HD showed a moder-
ate peritubular fibrosis, with Sirius red 
collagen accumulation observed mainly 
around the S1-S2 portion of the prox-
imal convoluted tubule. Interestingly, 
chronic BAY 11-7082 administration 
as well as NLRP3 inflammasome defi-
ciency blunted the diet-induced activa-
tion of the TGF-β/Smad2 profibrotic 
signaling cascade and the renal collagen 
accumulation.
Diet-induced NLRP3 activation 
Was Suppressed by BaY 11-7082 
administration or NLRP3 Gene 
Silencing
HD caused a marked increase in 
expression of NLRP3 and activated 
caspase-1 in WT mice (Figure 7), which 
was paralleled by a robust increase in 
expression of IL-1β and IL-18 mRNA 
(Supplementary Figure S2) associated 
with upregulated local and systemic 
concentrations of mature IL-1β and 
IL-18 (Figure 8). Chronic treatment 
with BAY 11-7082 reduced the expres-
sion of the components of the NLRP3 
inflammasome complex as well as the 
mRNA levels and active forms of the 
cytokines IL-1β and IL-18. In the kid-
ney (but not in the liver), the levels of 
IL-1β and IL-18 in the HD+BAY group 
NLRP3–/– mice fed the experimental diet 
in  comparison to control NLRP3–/– mice 
(263.95 ± 48.18 versus 114.03 ± 41.94 μg/mg, 
P < 0.05). However, the diet- induced 
increase in ACR in HD KO was signifi-
cantly lower than that recorded in HD 
WT mice (P < 0.05).
 albuminuria (401.23 ± 33.16 versus 98.06 ± 
13.16 μg/mg, P < 0.05; Figure 5F). Admini-
stration of BAY 11-7082 significantly 
attenuated the diet-induced rise in 
ACR (271.36 ± 5.63 versus 401.23 ± 
33.16 μg/mg, P < 0.05). An impaired ACR 
was also recorded in the kidney of 
Figure 3. Effects of diet manipulation and NLRP3 inflammasome inhibition or silencing 
on GLUT-4 expression in the skeletal muscle. Western blot analysis of GLUT-4 (A) and 
AS160 total protein expression and Thr642 phosphorylation (B) were performed in the liver 
and gastrocnemius of NLRP3–/– KO and WT mice treated or not with BAY 11-7082 (BAY, 
3 mg/kg IP). The relative expression of the protein bands was expressed as relative opti-
cal density (O.D.) and standardized to the corresponding β-actin contents. The data are 
means ± SEM of pooled data from three separate experiments (n = 4–6 mice per group). 
★P < 0.05 versus ND WT.
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induced a robust induction of both IκBα 
phosphorylation and NF-κB activation 
in the livers and kidneys of NLRP3–/– 
mice, similar to that recorded in the HD 
WT group, thus indicating that NLRP3 
silencing does not affect NF-κB nuclear 
translocation.
DiSCUSSiON
In the present work, we demonstrated 
that NLRP3–/– deficiency exerts protec-
tive effects against the metabolic alter-
ations evoked by exposure to a high-fat 
diet combined with an overconsumption 
of the simple sugar fructose, for which 
use as a sweetener in food processing 
BaY 11-7082 administration, but 
Not NLRP3 Silencing, inhibited Diet-
induced NF-jB activation
When compared with WT mice exposed 
to control diet, mice that underwent the 
experimental diet showed an increased 
phosphorylation of IκBα on Ser32/36 
(Figures 9A, C), which was associated 
with an increased translocation of the 
p65 NF-κB subunit from the cytosol 
to the nucleus (Figures 9B, D), in both 
liver and kidney. In contrast, chronic 
 administration of BAY 11-7082 to HD 
WT mice diminished both IκBα phos-
phorylation and p65 nuclear transloca-
tion (Figure 9B). The experimental diet 
remained higher than those in the ND 
WT group. As expected, the NLRP3 
inflammasome complex was not acti-
vated in KO mice and, hence, the HD 
diet did not trigger the production of 
the active forms of IL-1β and IL-18 in 
these mice. The significant reduction 
in systemic and local levels of NLRP3 
inflammasome-dependent cytokines, 
but not IL-6 (Supplementary Figure S3), 
by BAY 11-7082 administration or 
NLRP3–/– gene silencing confirm that 
the prevention/reduction of the HD- 
induced metabolic alterations were sec-
ondary to the lack of activation of the 
inflammasome.
Figure 4. Effects of diet manipulation and NLRP3 inflammasome inhibition or silencing on liver lipid accumulation and inflammation. 
(A) Representative photomicrographs (40× magnification) of oil red O staining on liver sections from either NLRP3–/– KO or WT mice 
treated or not with BAY 11-7082 (BAY 3 mg/kg IP) and maintained on a normal diet (ND) or a high-fat high-sugar diet (HD). (B) Triglyceride 
(TG) content in mouse liver. (C) TNF-α concentrations in mouse liver. Data are mean ± SEM of four to six animals per group. ★P < 0.05 
versus ND WT.
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effects could be due to interferences 
up- or downstream of inflammasome 
activation. Only the evaluation of small 
molecules that are able to selectively 
inhibit the NLRP3 inflammasome may 
allow the future design of novel and ef-
fective therapeutics for diseases caused 
by excessive activation of the NLRP3 
inflammasome. However, efficacious 
NLRP3 inflammasome inhibitors are still 
at an early stage of development. BAY 
11-7082 is one of the few compounds 
that has been demonstrated to directly 
target the NLRP3 inflammasome and 
selectively inhibits the ATPase activity 
of NLRP3 required for its activation (24). 
Our study provides the first evidence 
that the chronic administration of BAY 
11-7082 protects against the diet-induced 
metabolic alterations and that the qual-
itative and quantitative effects of BAY 
11-7082 (with very minor exceptions 
discussed below) are similar to those re-
corded in NLRP3–/– mice. The improved 
glucose tolerance here documented was, 
at least in part, due to an improvement 
in the signaling pathway of insulin in 
HD-fed mice. The IRS-1/Akt/GSK-3β 
cascade is a key regulator of glucose 
transportation, glycogen synthesis and 
glycolysis (25). Here we demonstrated 
that the defects in the  insulin signaling 
observed in both the livers and skeletal 
muscles of HD-fed mice could be re-
stored by pharmacological inhibition of 
NLRP3 activity. Accordingly, the dietary 
manipulation did not evoke any signif-
icant impairment in phosphorylation of 
IRS-1, Akt and GSK-3β, a substrate of 
Akt, in NLRP3–/– mice, thus confirming 
that NLRP3 suppression potentiates Akt 
activity. NLRP3 suppression was associ-
ated with a significant improvement in 
expression and membrane translocation 
of GLUT-4, the most abundant glucose 
transporter isoform in skeletal muscle 
(26), thus facilitating glucose transport. 
As previous findings convincingly 
showed that Akt regulates translocation, 
targeting and fusion of GLUT-4–con-
taining vesicles in mouse skeletal myo-
cytes (27,28), we speculate that GLUT-4 
translocation and subsequent glucose 
diseases has been poorly investigated. 
There are limited experimental data 
showing that pharmacological tools may 
ameliorate diabetic injury by regulating 
NLRP3 inflammasome activity (20–23). 
However, none of the proposed pharma-
cological strategies is based on the use 
of selective and specific NLRP3 inflam-
masome inhibitors. Thus, the described 
has dramatically increased over the last 
decade. Prior observations indicated that 
activation of the NLRP3 inflammasome 
plays a role in T2DM pathogenesis, pos-
sibly by driving inflammation, obesity 
and insulin resistance (7,9,10,18,19). 
Nevertheless, its role as specific phar-
macological target for drug therapy of 
insulin resistance and related metabolic 
Figure 5. Effects of diet manipulation and NLRP3 inflammasome inhibition or silencing 
on kidney structure and function. (A–E) Histological appearance of kidneys from  either 
NLRP3–/– KO or WT mice treated or not with BAY 11-7082 (BAY, 3 mg/kg IP) and main-
tained on a normal diet (ND) or a high-fat high-sugar diet (HD). (F) Urinary albumin-to- 
creatinine (ACR) levels in the absence or presence of diet manipulation and BAY 11-7082 
treatment. Values are mean ± SEM of four to six animals per group. ★P < 0.05 versus ND 
WT; •P < 0.05 versus HD WT; ♦P < 0.05 versus HD KO.
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uptake in skeletal muscle after NLRP3 
modulation is mainly due to activation 
of the IRS-1/Akt/GSK-3β pathway. 
Overall, our data demonstrate for the 
first time that activation of the NLRP3 
inflammasome directly modulates the 
Akt pathway, thus affecting a crucial 
pathogenic mechanism responsible for 
the development of insulin resistance. 
Preservation of insulin sensitivity may 
also account for the improved lipid 
profile detected in both HD+BAY WT 
and HD KO groups. As previously 
documented (29), the hyperinsulinemic 
state due to chronic exposure to HD may 
induce greater lipid accumulation, thus 
enhancing lipotoxicity. Mice exposed to 
HD showed obvious lipid accumulation, 
Figure 6. Effects of diet manipulation and NLRP3 inflammasome inhibition or silencing on hepatic and renal fibrotic response. Western 
blot analysis of TGF-β (A, D) and Smad2 (B, E) proteins in the liver and kidney of NLRP3–/– KO or WT mice exposed or not to diet manipula-
tion in the absence or presence of BAY 11-7082 (BAY, 3 mg/kg IP). Representative Sirus red staining of liver and kidney sections from WT 
or KO mice fed a control diet, HD diet in the absence or presence of BAY 11-7082 (BAY, 3 mg/kg IP) are reported in (C) and (F), respec-
tively. The autoradiograms reported here are representative of three independent experiments. The relative expression of the protein 
bands was expressed as relative optical density (O.D.) and standardized to the corresponding β-actin contents. The data are means ± 
SEM of pooled data from three separate experiments (n = 4–6 mice per group). ★P < 0.05 versus ND WT.
Figure 7. Western blot analysis of NLRP3, procaspase-1 and activated caspase-1 proteins 
in the liver and kidney of NLRP3–/– KO or WT mice exposed or not to diet manipulation 
in the absence or presence of BAY 11-7082 (BAY, 3 mg/kg IP). The autoradiograms here 
 reported are representative of three independent experiments.
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similar  activation of this inflammatory 
machinery in the kidney of mice ex-
posed to an excessive intake of fructose 
(12). Inflammatory microenvironments 
have been previously demonstrated to 
promote TGF-β signaling, which in turn 
can stimulate Smad2/3 phosphorylation, 
thus increasing profibrogenic responses 
in the liver and kidney (31,32).
 In this study, collagen deposition 
in liver was not detectable and was 
minimal in kidneys of HD WT mice, 
despite significant sustained inflam-
mation. However, we could detect a 
robust increase in TGF-β levels in both 
liver and kidney of WT mice after HD 
exposure, and this effect was associ-
ated with enhanced phosphorylation 
of Smad2, which has an essential role 
in the development and progression 
of  obesity-related liver and kidney 
diseases. Recently, the TGF-β/Smad2 
signaling has also been shown to be 
involved in regulating insulin gene tran-
scription and energy homeostasis (33). 
Thus, on the basis of our data, it appears 
that HD diet induces a local inflamma-
tory response, resulting in activation of 
the TGF-β/Smad2 signaling, which may 
potentially contribute to development 
of insulin resistance and to late liver 
and kidney fibrosis (not yet detectable 
at the time point here measured). Our 
observation is in concordance with 
previous reports indicating that local 
inflammation precedes fibrosis, when 
the latter is determined by measuring 
collagen production and accumulation 
(34,35). Our data showing reduced ac-
tivation of the TGF-β/Smad3 signaling 
in KO mice exposed to the same diet 
manipulation raise the possibility of 
an involvement of the NLRP3 inflam-
masome pathway in modulation of the 
early markers of fibrosis. The present 
study did not aim to elucidate the exact 
mechanisms mediating the liver and 
kidney injury evoked by NALP3 in-
flammasome activation. However, we 
speculate that the diet-induced increased 
production of inflammatory cytokines, 
such as IL-1β and IL-18, resulting from 
activation of NALP3 inflammasomes, 
the mouse kidney attenuated both renal 
injury (histology) and dysfunction (al-
buminuria) caused by HD. Consistent 
with our  results, a recent study showed 
that a high-fat diet increases NLRP3 
inflammasome activity in glomeruli, 
resulting in glomerular inflammation 
and consequent glomerular injury (30). 
Moreover, we previously observed a 
and hepatic steatosis was associated with 
local activation of NLRP3 inflammasome. 
Interestingly, NLRP3 gene silencing as 
well as BAY 11-7082 treatment effec-
tively prevented lipid accumulation as 
well as local and systemic inflammation 
by sup pressing the release of TNF-α, 
IL-1β and IL-18. Similarly, inhibition of 
NLRP3 inflam masome activity within 
Figure 8. Effects of diet manipulation and NLRP3 inflammasome inhibition or silencing on 
local and systemic levels of IL-1β and IL-18. IL-1β and IL-18 concentrations were analyzed 
by ELISA in liver (A, B), kidney (C, D) and serum (E, F) of NLRP3–/– KO or WT mice main-
tained on a normal diet (ND) or a high-fat high-sugar diet (HD), in the absence or pres-
ence of BAY 11-7082 (BAY, 3 mg/kg IP). Data are means ± SEM of four to six animals per 
group. ★P < 0.05 versus ND WT.
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dietary manipulation (43). Thus, both 
NF-κB nuclear translocation and activa-
tion of the NLRP3  inflammasome path-
way coordinately contribute to insulin 
resistance in obesity. Here we demon-
strated a diet-induced activation of the 
NF-κB pathway in both liver and kidney 
and we confirmed that the administra-
tion of BAY 11-7082 inhibited phosphory-
lation and subsequently the degradation 
of IκBs, which reduces nuclear trans-
location of NF-κB via its sequestration 
in an inactive state in the cytoplasm. 
Intriguingly, the inhibition of NF-κB 
activity was not seen in organs from 
NLRP3 KO mice. Thus, based on the 
considerable qualitative and quantitative 
similarities between the pharmacological 
effects elicited by BAY 11-7082 and the 
NLRP3 gene silencing in our experi-
mental conditions, we speculate that 
of NLRP3 inflammasome-dependent 
cellular and molecular events mediating 
the protective effects of BAY 11-7082 
against diet-induced metabolic abnor-
malities. It has to be stressed, however, 
that BAY 11-7082 is not only an inhibitor 
of NLRP3 inflammasome activity, since 
this molecule may act also as an inhibi-
tor of NF-κB activation and other inflam-
matory signaling pathways (42). For this 
reason, we also investigated the effects 
of BAY 11-7082 on NF-κB nuclear trans-
location, since BAY 11-7082 is known to 
block IκBα phosphorylation and the sub-
sequent NF-κB activation, independently 
of its inhibitory effects on NLRP3 inflam-
masome formation and activation (24). 
Suppression of the NF-κB pathway by 
targeted KO mice or pharmacological 
inhibition of this pathway can reduce 
insulin resistance in mice exposed to 
may act in an autocrine or paracrine 
fashion to change hepatic and renal cell 
function. Moreover, we cannot rule out 
a contribution of the “non-inflammatory 
effects” of NALP3 inflammasome acti-
vation such as pyroptosis, cytoskeleton 
changes and alteration of cell metabo-
lism, which have also been reported to 
mediate the detrimental local action of 
inflammasome activation (36,37). An-
other unresolved question is whether 
the NLRP3 inflammasome activation 
occurs at the level of resident cells, since 
results so far obtained from preclinical 
models of obesity and insulin resistance 
are quite contrasting. There is good 
evidence that both hematopoietic and 
nonhematopoietic cells are involved in 
NLRP3 inflammasome activation in both 
renal and hepatic tissues (38–41). The 
above data provide evidence in support 
Figure 9. Effects of diet manipulation and NLRP3 inflammasome inhibition or silencing on NF-κB signaling pathway. Signaling events were 
assessed in liver (A, B) and kidney (C, D) tissues from NLRP3–/– KO or WT mice maintained on a normal diet (ND) or a high-fat high-sugar 
diet (HD), in the absence or presence of BAY 11-7082 (BAY, 3 mg/kg IP). The relative expression of the protein bands was expressed as 
relative optical density (O.D.) and standardized to the corresponding β-actin contents. NF-κB p65 subunit translocation was evaluated 
expressing p65 subunit levels as a nucleus:cytosol ratio corrected for the β-actin contents and normalized using the ND WT band. The 
data are means ± SEM of pooled data from three separate experiments (n = 4–6 mice per group). ★P < 0.05 versus ND WT; •P < 0.05 
 versus HD WT; ♦P < 0.05 versus ND KO.
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108:15324–9.
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18. Goossens GH, et al. (2012) Expression of NLRP3 
inflammasome and T cell population markers 
in adipose tissue are associated with insulin 
resistance and impaired glucose metabolism in 
humans. Mol. Immunol. 50:142–9.
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renal NLRP3 inflammasome activation and lipid 
accumulation. PLoS One. 7:e38285.
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hepatic metaflammation and inhibits NLRP3 
 inflammasome activation. Metabolism. 63:693–701.
22. Honda H, et al. (2014) Isoliquiritigenin is a potent 
inhibitor of NLRP3 inflammasome activation and 
diet-induced adipose tissue inflammation. J. Leukoc. 
Biol. 96:1087–100.
23. Shan Q, et al. (2014) Purple sweet potato color 
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stress mediated NLRP3 inflammasome  activation 
in high fat diet mice. Food Chem. Toxicol. 69:339–46.
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immunosuppressive effects and better 
pharmacokinetics and cost-effectiveness. 
Further preclinical and clinical studies 
are needed to further explore this pos-
sibility and to investigate/ensure the 
safety of this innovative pharmacologi-
cal approach.
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